Nastoyashchee i budushchee farmakoterapii akromegalii


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article analyzes the main methods of treatment of acromegaly. Over the past decade, the advanced pharmacological agents that promote the normalization of impaired somatotropic function are actively introduced in a global endocrinological practice. This includes non-selective and selective dopamine agonists, somatostatin analogues and growth hormone receptor blockers. The main drug groups and the recommended regimen for their use are presented.

Full Text

Restricted Access

References

  1. Mestron A., Webb, R. Astorga, et al. Epidemiology, clinical characteristics, outcome, morbidity and mortality in acromegaly basel on the Spanish Acromegaly Registry (Registro Espanol de Acromegalia, REA) Europ J Endocrinol 2004; 151:1-9.
  2. Dekkers O.M., Biermasz N.R., Pereira A.M., et al. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 2008;93:61 - 7.
  3. Melmed S., Colao A., Barkan A., et al. Guidelines for Acromegaly Management: An Update. J Clin Endocrinol Metab 2009;94(5): 1509-17.
  4. AACE Acromegaly Guidelines Task Force, AACE Medical Guidelines for Clinical Practice for the diagnosis and treatment of acromegaly. Endocr Pract 2004; 10(3 ):213-25.
  5. Молитвословова Н.Н. Акромегалия: современные достижения в диагностике и лечении // Проблемы эндокринологии 2011. № 1. С. 46-59.
  6. Акромегалия: патогенез, клиника, диагностика, дифференциальная диагностика, методы лечения. Пособие для врачей / Под ред. И.И. Дедова, Г.А. Мельниченко. М., 2012.
  7. Григорьев А.Ю., Азизян В.Н. Эндоскопическая хирургия аденом гипофиза. Практическое руководство для врачей / Под ред. И.И. Дедова. М., 2011.
  8. Colao A., Attanasio R., Pivonello R., et al. Partial surgical removal of growth hormone-secreting pituitary tumors enhances the response to somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2006;91:85-92.
  9. Del Porto L.A., Liubinas S.V., Kaye A.H. Treatment of persistent and recurrent acromegaly. J Clin Neurosci 2011;18(2):181-90.
  10. Karavitaki N., Turner H.E., Adams C.B., et al. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide. Clin Endocrinol (Oxf) 2008;68:970-75.
  11. Petrossians P. Borges-Martins L, Espinoza C, et al. Gross total resection or debulking of pituitary adenomas improves hormonal control of acromegaly by somatostatin analogs. Eur J Endocrinol 2005;152:61-6.
  12. Petersenn S., Buchfelder M., Reincke M., et al. Results of surgical and somatostatin analog therapies and their combination in acromegaly: a retrospective analysis of the German Acromegaly Register. Eur J Endocrinol 2008; 159(5):525-32.
  13. Sheehan J.M., Douds G.L., Hill K. Transsphenoidal surgery for pituitary adenoma in elderly patients. Acta Neurochir 2008; 150(6):571-74.
  14. Krzentowska-Korek A., Golkowski F., Baldys-Waligorska A., et al. Efficacy and complications of neurosurgical treatment of acromegaly. Pituitary 2011;14(2):157-62.
  15. Vik-Mo E.O., Oksnes M., Pedersen P.H., et al. Gamma knife stereotactic radiosurgery for acromegaly. Eur J Endocrinol 2007; 157(3):255-63.
  16. Brada M., Ashley S., Ford D., et al. Cerebrovascular mortality in patients with pituitary adenoma. Clin Endocrinol (Oxf) 2002;57:713-17.
  17. Berkmann S.M., Tolnay, D. Hanggi, et al. Sarcoma of the sella after radiotherapy for pituitary adenoma. Acta Neurochir (Wien) 2010;152(10):1725-35.
  18. Verhelst J.A., Abrams R. Abs Remission of acromegaly following long-term therapy with cabergoline: report of two cases. Pituitary 2008;11(1):103-7.
  19. Vilar L., Czepielewsk M.A., L.A. Naves et al. Substantial shrinkage of adenomas cosecreting growth hormone and prolactin with use of cabergoline therapy. Endocr Pract 2007;13(4):396-402.
  20. Cozzi R., R. Attanasio, S. Lodrini, et al. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf) 2004;61:209-15.
  21. Croxtall J.D., Scott L.J., Lanreotide Autogel. A review of its use in the management of acromegaly, Drugs 2008;68:711-23.
  22. Schopohl J., Strasburger C.J., Caird D., et al. Efficacy and Acceptability of Lanreotide Autogel 120 mg at Different Dose Intervals in Patients with Acromegaly Previously Treated with Octreotide LAR. Experimental and Clinical Endocrinology & Diabetes 2011;119:156-62.
  23. Utuncu Y., Berker D., Isik S. Comparison of octreotide LAR and lanreotide autogel as postoperative medical treatment in acromegaly. Putuitary 2012;15(3):398-404.
  24. Freda P.U. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002;87(8):3013-18.
  25. Maiza J.C., Vezzosi D., Matta M., et al. Long-term (up to 18 years) effects on GH/IGF-1 hypersecretion and tumour size of primary somatostatin analogue (SSTa) therapy in patients with GH-secreting pituitary adenoma responsive to SSTa. Clin Endocrinol (Oxf) 2007;67:282-89.
  26. Murray R.D., Melmed S. A Critical Analysis of Clinically Available Somatostatin Analog Formulations for Therapy of Acromegaly / J Clin Endocrinol Metab 2008;93(8):2957-67.
  27. Aisley A.N., Rowles S.V., Roberts M.E., et al. Treatment of acromegaly improves quality of life, measured by AcroQol. Clin Endocrinol (Oxf) 2007; 67(3):358-62.
  28. Bevan J.S. The anti-tumoral effects of somatostatin analog therapy in Acromegaly. J Clin Endocrinol Metab 2005;90:1856-63.
  29. Casarini A.P., Jallad R.S., Pinto E.M., et al. Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment. Pituitary 2009; 12(4):297-303.
  30. Van der Lely A.J., Nutson R.K., Trainer P.J., et al. Long-term treatment of acromegaly with pegvisomant, a growth hormone receptor antagonist. Lancet 2001 ;358(9725): 1754-59.
  31. Trainer P.J., Drake W.M., Katznelson L., et al. Treatment of Acromegaly with the Growth Hormone-Receptor Antagonist Pegvisomant. New En J Med 2000;342(16):1171-77.
  32. Jallad R.S., Musolino N.R., Salgado L.R., et al. Treatment of acromegaly with octreotide-LAR: extensive experience in a Brazilian institution / Clin Endocrinol (Oxf) 2005; 63(2):168-75.
  33. Tulipano G., C. Bonfanti, G. Melani, et al. Differential inhibition of growth hormone secretion by analogs selective for somatostatin receptor subtypes 2 and 5 in human growth-hormone secreting adenoma cells in vitro. Neuroendocrinology 2001;73:344-51.
  34. Ferone D., de Herder W.W., Pivonello R., et al. Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. J Clin Endocrinol Metab 2008;93:1412-17.
  35. Plöckinger U., Albrecht S., Mawrin C., et al. Selective Loss of Somatostatin Receptor 2 in Octreotide-Resistant Growth Hormone -Secreting Adenomas. J Clin Endocrinol Metab 2008;93(4): 1203-10.
  36. Delesque N., Buscail L., Esteve J.P. et al. sst2 somatostatin receptor expression reverses tumorigenicity of human pancreatic cancer cells. Cancer Res 1997;57:956-62.
  37. Kim H.J., Park M.S., Kim S.W., et al. Prevalence of Gs alpha mutations in Korean patients with pituitary adenomas. J Endocrinol 2001; 168:221 -26.
  38. Mendoza V., Sosa E., Espinosa-de-Los Monteros A.I., et al. GSP alpha mutations in Mexican patients with acromegaly: potential impact on long term prognosis. Growth Hormone and IGF Research 2005;15:28-32.
  39. Dasgupta P. Somatostatin analogues: multiple roles in cellular proliferation, neoplasia, and angiogenesis. Pharmacol Ther 2004; 102:61-85.
  40. Pisarek H., Pawlikowski M., Kunert-Radek J., et al. Expression of somatostatin receptor subtypes in human pituitary adenomas - immunohistochemical studies. Endocrinol Pol 2009;60(4):240-51.
  41. Gola M., Bonadonna S., Mazziotti G., et al. Resistance to somatostatin analogs in acromegaly: an evolving concept? J Endocrinol Invest 2006;29:86-93.
  42. Пронин В.С., Анциферов М.Б., Алексеева Т.М. и др. Прогностические факторы эффективности медикаментозного лечения акромегалии // Врач 2010. № 2. С. 39-43.
  43. Colao A. Beneficial effect of dose escalation of Octreoti-Lar as first-line therapy in patients with acromegaly. Eur J Endocrinol 2007;157:579-87.
  44. Giustina A., Bonadonna S., Bugari G., et al. High-dose intramuscular octreotide in patients with acromegaly inadequately controlled on conventional somatostatin analogue therapy: a randomized trial. Eur J Endocrinol 2009; 161:331 -38.
  45. Fleseriu M. Clinical efficacy and safety resuts for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review. Springer, Pituitary. doi: 10.1007/s11102-010-0282-z. Published online: 2010.
  46. De Marinis L., Bianchi A., Fusco A., et al. Long-term effects of the combination of pegvisomant with somatostatin analogs (SSA) on glucose homeostasis in non-diabetic patiens with active acromegaly partially resistant to SSA. Pituitary 2007; 10(3):22 7-
  47. Cozzi R., Attanasio R., Lodrini S., et al. Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. Clin Endocrinol (Oxf) 2004;61:209-15.
  48. Selvarajah D., Webster J., Ross R., et al. Effectiveness of adding dopamine agonist therapy to long-acting somatostatin analogues in the management of acromegaly. Eur J Endocrinol 2005;152:569-74.
  49. Анциферов М.Б., Пронин В.С., Алексеева Т.М. Медикаментозное лечение пациентов с акромегалией, частично резистентных к терапии аналогами соматостатина // Фарматека 2011. № 16. С. 49-55.
  50. Sandret L., Maison P., Chanson P. Place of cabergoline in acromegaly: a meta-analysis J Clin Endocrinol Metab 2011;96(5):1327-35.
  51. Fleseriu M. Clinical efficacy and safety results for dose escalation of somatostatin receptor ligands in patients with acromegaly: a literature review. Pituitary 2011;14(2):184-93.
  52. Ben-Shlomo A., Melmed S. Pasireotide - a somatostatin analog for the potential tratment of acromegaly, neuroendocrine tumors and Cushings disease. IDrugs 2007;10(12):885-95.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies